Background: Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route.
Aims: This study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures.
Settings and design: This cross-sectional study was conducted in 2019 for patients treated with either warfarin or apixaban at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.
Methods: We used a series of descriptive statistics to examine the differences in sociodemographic characteristics among patients. A propensity score-matching approach was employed to reduce the effect of confounding variables that often influence treatment selection. Greedy matching approach was used to analyze the QOL.
Results: A total of 388 patients were identified, of which 124 were matched between the two groups (62 patients in each group). Most of the patients were female, married, below the sufficiency level, educated, and nonsmokers. The patients using warfarin had a significantly better health state (M = 69.64, standard deviation [SD] = 16.52) than those using apixaban (M = 66.33, SD = 23.17), P = 0.011.
Conclusions: Future studies should explore why patients using apixaban showed lower QOL scores and improve health-care providers' awareness of these issues.
Keywords: Apixaban; EuroQoL; oral anticoagulants; patient-reported outcomes; propensity score matching; warfarin.
Copyright: © 2020 Annals of Thoracic Medicine.